Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05244980 · ClinicalTrials.gov registry record · Phase 1
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 1 study of Alopecia, Androgenetic, sponsored by Technoderma Medicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT05244980 is a Phase 1 study of Alopecia, Androgenetic that has completed, run by Technoderma Medicines. The registered enrollment target is 32 participants, below the 339-participant average among 3 other Alopecia, Androgenetic trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05244980, a Phase 1 study of Alopecia, Androgenetic, has completed, sponsored by Technoderma Medicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TDM-105795
Study Locations (2)
California
- TCR Medical Corporation - San Diego
Texas
- J&S Studies, Inc. - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05244980
The ClinicalTrials.gov registry entry for NCT05244980 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 339-participant average among 3 other Alopecia, Androgenetic trials with a reported enrollment target (91% lower). The listed sponsor is Technoderma Medicines, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia, Androgenetic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05244980 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT05244980 about?
NCT05244980 is a clinical study titled "A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)". Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
What is the current status of trial NCT05244980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-02-01. Estimated completion is 2023-02-27.
What conditions does trial NCT05244980 study?
This clinical trial studies the following conditions: Alopecia, Androgenetic.
What interventions are being tested in trial NCT05244980?
The interventions under investigation include: Placebo (DRUG), TDM-105795 (DRUG).
Who is sponsoring clinical trial NCT05244980?
This trial is sponsored by Technoderma Medicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05244980 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia, Androgenetic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
ACTIVE NOT RECRUITING · Phase 3
-
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
COMPLETED · Phase 2
-
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.